NAVINCHANDRA MEHTA INSTITUTE OF TECHNOLOGY AND DEVELOPMENT

MMS SEM-3
Priyanka Shukla Aditya Shelke Rahul Pandey Salil Koske Priyank Barbat M-2125 M-2125 M-2125 M-2125 M-2125

Presents

A
Presentation on

RANBAXY
Largest pharmaceutical company out of India with global reach and competencies across the value chain

CONTENTS
INTRODUCTION MISSION &VALUES

GLOBAL PRESENCE
JOURNEY MODE OF ENTRY

THE GLOBAL GENERICS ADVANTAGES

COMPETITIVE ADVANTAGES RESEARCH & DEVELOPMENT GLOBAL MANUFACTURING STRENGTH DEVELOPED MARKET PRESENCE EMERGING MARKET PRESENCE CORPORATE SOCIAL RESPONSIBILITY

INTRODUCTION

 Founded in 1961 Ranbaxy was started by Ranbir Singh and Gurbax Singh in

1937 as a distributor for a Japanese company Shionogi

India's largest pharmaceutical companies , Ranbaxy & Daiichi

Sankyo combined rank among the top 20 global pharmaceutical companies

Worldwide Presence -

Ground presence in 46 countries, products sold in over

125 countries Manufacturing locations in 8 countries

 Highest R&D spender amongst Indian Pharmaceutical

companies Business International Domestic

77% 23%

Around 14000 employees globally represented by 50

nationalities One of the largest distribution networks that comprises over 4000 field force Project 'Viraat' - A key initiative to strengthen company's domestic leadership position

MISSION & VALUES

MISSION Enriching lives globally, with quality and affordable pharmaceuticals

VALUES Achieving customer satisfaction is fundamental to our business Provide products and services of the highest quality Practice dignity and equity in relationships and provide opportunities for our people to realize their full potential Ensure profitable growth and enhance wealth of the shareholders Foster mutually beneficial relations with all our business partners Manage our operations with high concern for safety and environment Be a responsible corporate citizen

GLOBAL PRESENCE

BRICS
No. 1 in India Large, reputed player in CIS; growing rapidly No. 6 in Brazil No. 5 in S. Africa

Other Emerging Markets

43/54 countries in Africa Latam & Asia Pacific: long standing presence; good understanding; robust businesses

North America & Japan

Pioneer entrant from India Strong local presence Canada: New market, growing rapidly

Europe
Well established 23/25 EU markets No. 1 Generic player in Romania

 In June 2008, Daiichi-Sankyo acquired a 34.8% stake in

Ranbaxy, for a value $2.4 billion

In November 2008, Daiichi-Sankyo completed the takeover of

the company from the founding Singh family in a deal worth $4.6 billion by acquiring a 63.92% stake in Ranbaxy
Significant and sustained operational and strategic synergies

across the globe

Combining innovator and generics capabilities, to straddle full

spectrum of pharma value chain

HEADQUARTERS

LOCATED AT GURGAON, NEW DELHI

JOURNEY

MODE OF ENTRY

 Foreign Direct Investment(FDI) Joint Venture Acquisition Licensing

STRATEGY

 Follows a geocentric approach It is the Companys constant endeavour to provide a wide

basket of generic and innovator products, leveraging the unique Hybrid Business Model with Daiichi Sankyo

BUSINESS MODEL

THE GLOBAL GENERICS ADVANTAGES

COMPETITIVE ADVANTAGES

RESEARCH & DEVELOPMENT

 Dedicated Facilities for Innovative & Generics Research

More than 1200 R&D Personnel Highest R&D spender amongst Indian Pharmaceutical

companies
NDDS based products (4 platform technologies)
NDDR - Arterolane + PQP (Anti malaria) One program with GSK (Respiratory)

Collaboration in Clinical Development of NCE

GLOBAL MANUFACTURING STRENGTH

 7 manufacturing locations worldwide API facilities - increasing vertical integration Creating capacities for specialty products New facilities added in cost advantageous geographies

USA

IRELAND

ROMANIA

NIGERIA

INDIA

SOUTH AFRICA

MALAYSIA

DEVELOPED MARKET PRESENCE

 USA
Largest generic market worldwide Significant patent expiries through 2015 EUROPEAN UNION Germany, UK - mature markets France, Spain, Italy, Romania - emerging markets

Ranbaxy has presence in 23 of the 27 EU countries

JAPAN

Emerging generic market

Opportunity to develop, manufacture & supply products through

Daiichi Sankyo

EMERGING MARKET PRESENCE

 INDIA Among India's largest pharmaceutical companies Growing at a fast pace

ROMANIA
Ranked as the No. 1 Generics Company Strategic for servicing EU operations RUSSIA & UKRAINE Strong base in acute therapies Fast expanding into chronic and OTC segments SOUTH AFRICA Key market in the African continent

A strong No. 5 player in the region

Corporate social responsibility